(-)-Irofulven
Based on 1 publication(s) in Google Scholar
(-)-Irofulven (MGI 114), an Illudin S analog, is a DNA alkylating agent. (-)-Irofulven inhibits the replication of DNA, induces tumor cells apoptosis, and has potent antitumor activity.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 97.68%
- CAS No.: 158440-71-2
- Formule: C15H18O3
- Masse moléculaire:246.31
-
Stockage:Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) (-)-Irofulven
More
Activité biologique
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | IC50 |
1.2 μM
Compound: (-)-HMAF
|
Cytotoxicity against HEK293 cells by MTT assay
Cytotoxicity against HEK293 cells by MTT assay
|
[PMID: 16610802] |
| HEK293 | IC50 |
55 nM
Compound: (-)-HMAF
|
Cytotoxicity against HEK293 cells transfected with recombinant AOR by MTT assay
Cytotoxicity against HEK293 cells transfected with recombinant AOR by MTT assay
|
[PMID: 16610802] |
| HL-60 | IC50 |
73 nM
Compound: 5, HMAF, MGI114
|
Cytotoxicity against human HL60 cells after 48 hrs by trypan blue exclusion method
Cytotoxicity against human HL60 cells after 48 hrs by trypan blue exclusion method
|
[PMID: 8864242] |
| HL-60 | IC50 |
73 nM
Compound: irofulven
|
Cytotoxicity against human HL60 cells after 48 hrs by trypan blue exclusion assay
Cytotoxicity against human HL60 cells after 48 hrs by trypan blue exclusion assay
|
[PMID: 12608875] |
(-)-Irofulven (2.8 μM; 1 hour) induces p53-dependent cell cycle arrest[1].
(-)-Irofulven (0.8 μM, 0.9 μM and 2.8 μM; 1 hour) induces CHK2 activation is related to p53 status in cells[1].
(-)-Irofulven inhibits DNA replication and induces chromosome aberrations (breaks and radials)[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:A2780, CAOV3 and HCT116 cells
-
Concentration:2.8 μM
-
Incubation Time:1 hour
-
Result:p53 wild-type cells mainly arrested at G1/S phases, while p53-mutated or p53-null cells arrested at S and G2/M phases.
-
Cell Line:A2780, CAOV3 and HCT116 cells
-
Concentration:0.8 μM, 0.9 μM and 2.8 μM
-
Incubation Time:1 hour
-
Result:Induced the Thr 68 phosphorylation of CHK2 kinase in cells.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male and female athymic BALB/c mice (nu/nu genotype, 6 weeks old or older) injected with human glioblastoma multiforme[2].
-
Dosage:7 mg/kg
-
Administration:i.p; on days 1-5 and 8-12
-
Result:Was active against all tumor lines.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 158440-71-2
-
Appearance Solid
-
Masse moléculaire 246.31
-
Formule C15H18O3
-
Color Yellow to orange
-
SMILES
CC(C1(CC1)[C@@](O)(C2=O)C)=C3C2=CC(C)=C3CO
-
Synonyms
MGI 114; 6-Hydroxymethylacylfulvene; NSC 683863
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Powder -20°C 3 years In solvent -80°C 6 months -20°C 1 month
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Adv Sci (Weinh)
Glucose Deprivation-Induced Disulfidptosis via the SLC7A11-INF2 Axis: Pan-Cancer Prognostic Exploration and Therapeutic Validation. [Abstract]2025 Jul 25:e08556. PMID: 40709550
Solvant et solubilité
DMSO : 50 mg/mL (203.00 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (10.15 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (10.15 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Yutian Wang, et al. Irofulven induces replication-dependent CHK2 activation related to p53 status. Biochem Pharmacol. 2007 Feb 15;73(4):469-80. [Content Brief]
[2]. H S Friedman, et al. Activity of irofulven (6-hydroxymethylacylfulvene) in the treatment of glioblastoma multiforme-derived xenografts in athymic mice. Cancer Chemother Pharmacol. 2001 Nov;48(5):413-6. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.0600 mL | 20.3000 mL | 40.5999 mL | 101.4998 mL |
| 5 mM | 0.8120 mL | 4.0600 mL | 8.1200 mL | 20.3000 mL | |
| 10 mM | 0.4060 mL | 2.0300 mL | 4.0600 mL | 10.1500 mL | |
| 15 mM | 0.2707 mL | 1.3533 mL | 2.7067 mL | 6.7667 mL | |
| 20 mM | 0.2030 mL | 1.0150 mL | 2.0300 mL | 5.0750 mL | |
| 25 mM | 0.1624 mL | 0.8120 mL | 1.6240 mL | 4.0600 mL | |
| 30 mM | 0.1353 mL | 0.6767 mL | 1.3533 mL | 3.3833 mL | |
| 40 mM | 0.1015 mL | 0.5075 mL | 1.0150 mL | 2.5375 mL | |
| 50 mM | 0.0812 mL | 0.4060 mL | 0.8120 mL | 2.0300 mL | |
| 60 mM | 0.0677 mL | 0.3383 mL | 0.6767 mL | 1.6917 mL | |
| 80 mM | 0.0507 mL | 0.2537 mL | 0.5075 mL | 1.2687 mL | |
| 100 mM | 0.0406 mL | 0.2030 mL | 0.4060 mL | 1.0150 mL |
(-)-Irofulven Related Classifications
HY-14429 Related Classifications
Powered by Bioz